Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STK25 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
STK25 siRNA is a research-grade small interfering RNA (siRNA) designed to silence the expression of the STK25 gene (Serine/Threonine Kinase 25, also known as SOK1 or YSK1) through RNA interference (RNAi). STK25 is a Ste20-type kinase that plays a critical role in regulating lipid and glucose metabolism, inflammatory signaling, and cellular stress responses. In preclinical research, STK25 siRNA is utilized to investigate the kinase's involvement in metabolic disorders such as type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), as well as its role in oncogenic pathways and atherosclerosis. It is primarily available as a laboratory reagent from various life science suppliers and is not currently being developed as a clinical therapeutic.
- Other names
- SOK1 siRNASOK-1 siRNASOK 1 siRNAYSK1 siRNAYSK-1 siRNAYSK 1 siRNASerine/Threonine Kinase 25 siRNA
02
Targets
STK25 (Serine/threonine kinase 25)
Beyond the preview
Go deeper on STK25 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STK25 siRNA.